AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 20817382 — intervention group
Group type: EXPERIMENTAL
Intervention: MI sessions including a significant other (SO)
Number of subjects: 382
Study 20817382 — intervention group
Group type: COMPARATOR
Intervention: Individual MI sessions
Number of subjects: 382
Study 17626700 — intervention group
Group type: EXPERIMENTAL
Intervention: Health Tracker (HT) reports
Number of subjects: 1079
Study 17626700 — intervention group
Group type: COMPARATOR
Intervention: HT-nonviewers
Number of subjects: 1079
Study 15724754 — intervention group
Group type: EXPERIMENTAL
Intervention: FRC Postec bonded with Excite DSC/Variolink II
Number of subjects: 32
Study 15724754 — intervention group
Group type: EXPERIMENTAL
Intervention: FRC Postec bonded with Syntac/Variolink II
Number of subjects: 32
Study 15724754 — intervention group
Group type: EXPERIMENTAL
Intervention: FRC Postec bonded with Excite DSC/Experimental Self Cure Cement
Number of subjects: 32
Study 15724754 — intervention group
Group type: EXPERIMENTAL
Intervention: C-Post bonded with One Step/Hi-X
Number of subjects: 32
Study 15724754 — intervention group
Group type: COMPARATOR
Intervention: ParaPost Fiber White (self-cure control)
Number of subjects: 32
Study 15724754 — intervention group
Group type: EXPERIMENTAL
Intervention: Cosmopost (zirconia post)
Number of subjects: 32
Study 15724754 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium region of the root
Number of subjects: 32
Study 15724754 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical root region
Number of subjects: 32
Study 15724754 — intervention group
Group type: EXPERIMENTAL
Intervention: Apical region
Number of subjects: 32
Study 12471291 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical therapy treatment (McConnell-based)
Number of subjects: 65
Study 12471291 — intervention group
Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 65
Study 9830074 — intervention group
Group type: COMPARATOR
Intervention: Essential oils rinse
Number of subjects: 32
Study 9830074 — intervention group
Group type: COMPARATOR
Intervention: Chlorhexidine (CHX)
Number of subjects: 32
Study 9830074 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol-free chlorhexidine (0.12%)
Number of subjects: 32
Study 8120307 — intervention group
Group type: EXPERIMENTAL
Intervention: Influenza hemagglutinin-diphtheria toxoid conjugate vaccine (HA-D)
Number of subjects: 408
Study 8120307 — intervention group
Group type: COMPARATOR
Intervention: Influenza hemagglutinin-subunit vaccine (HA)
Number of subjects: 408
Study 2571296 — intervention group
Group type: EXPERIMENTAL
Intervention: Rilmenidine 1 mg
Number of subjects: 392
Study 2571296 — intervention group
Group type: COMPARATOR
Intervention: Clonidine
Number of subjects: 392
Study 2571296 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 392
Study 2571296 — intervention group
Group type: COMPARATOR
Intervention: Hydrochlorothiazide
Number of subjects: 392
Study 2571296 — intervention group
Group type: COMPARATOR
Intervention: Reference alpha 2‐agonists
Number of subjects: 392
Study 424690 — intervention group
Group type: EXPERIMENTAL
Intervention: Parietal cell vagotomy (PCV)
Number of subjects: 32
Study 424690 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective vagotomy with pyloroplasty (SV + P)
Number of subjects: 32
Study 31901705 — intervention group
Group type: EXPERIMENTAL
Intervention: COMBO450 (450 mg of encorafenib QD + 45 mg of binimetinib BID)
Number of subjects: 577
Study 31901705 — intervention group
Group type: EXPERIMENTAL
Intervention: ENCO300 (300 mg of encorafenib QD)
Number of subjects: 577
Study 31901705 — intervention group
Group type: COMPARATOR
Intervention: VEM (960 mg of vemurafenib BID)
Number of subjects: 577
Study 30640775 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous injection of TXA 100 mg/1 mL
Number of subjects: 131
Study 30640775 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 131
Study 30640775 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous injection of TXA 100 mg/1 mL in anticoagulant subgroup
Number of subjects: 131
Study 30640775 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline) in anticoagulant subgroup
Number of subjects: 131
Study 28796809 — intervention group
Group type: EXPERIMENTAL
Intervention: DP‐EES (everolimus-eluting stent)
Number of subjects: 455
Study 28796809 — intervention group
Group type: COMPARATOR
Intervention: DP‐SES (sirolimus-eluting stent)
Number of subjects: 455
Study 28796809 — intervention group
Group type: EXPERIMENTAL
Intervention: DP‐EES
Number of subjects: 455
Study 28796809 — intervention group
Group type: COMPARATOR
Intervention: DP‐SES
Number of subjects: 455
Study 25761916 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced dissemination strategy of the Go Sun Smart (GSS) program
Number of subjects: 909
Study 25761916 — intervention group
Group type: COMPARATOR
Intervention: Basic dissemination strategy of the Go Sun Smart (GSS) program
Number of subjects: 909
Study 25761916 — intervention group
Group type: EXPERIMENTAL
Intervention: Greater recall of messages (regardless of level of implementation)
Number of subjects: 909
Study 23638986 — intervention group
Group type: EXPERIMENTAL
Intervention: Microneedling-assisted PDT (MN-PDT)
Number of subjects: 10
Study 23638986 — intervention group
Group type: COMPARATOR
Intervention: Conventional methyl aminolevulinate (MAL) PDT
Number of subjects: 10
Study 23638986 — intervention group
Group type: EXPERIMENTAL
Intervention: Both MN-PDT and conventional MAL-PDT
Number of subjects: 10
Study 21306698 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic sacral colpopexy
Number of subjects: 108
Study 21306698 — intervention group
Group type: COMPARATOR
Intervention: Total vaginal mesh
Number of subjects: 108
Study 19491837 — intervention group
Group type: EXPERIMENTAL
Intervention: Baclofen (3 x 20 mg) during PPI treatment
Number of subjects: 27
Study 19491837 — intervention group
Group type: COMPARATOR
Intervention: Placebo during PPI treatment
Number of subjects: 27
Study 19396451 — intervention group
Group type: EXPERIMENTAL
Intervention: Ligasure diathermy hemorrhoidectomy under spinal anesthesia
Number of subjects: 74
Study 19396451 — intervention group
Group type: COMPARATOR
Intervention: Conventional diathermy hemorrhoidectomy under spinal anesthesia
Number of subjects: 74
Study 19396451 — intervention group
Group type: EXPERIMENTAL
Intervention: Ligasure diathermy hemorrhoidectomy under local anesthesia
Number of subjects: 74
Study 19396451 — intervention group
Group type: COMPARATOR
Intervention: Conventional diathermy hemorrhoidectomy under local anesthesia
Number of subjects: 74
Study 15240612 — intervention group
Group type: EXPERIMENTAL
Intervention: High-protein diet (40% carbohydrate, 30% protein)
Number of subjects: 32
Study 15240612 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard protein diet (55% carbohydrate, 15% protein)
Number of subjects: 32
Study 12899366 — intervention group
Group type: EXPERIMENTAL
Intervention: Duchenne smiling
Number of subjects: 0
Study 12899366 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-Duchenne smiling (low-level)
Number of subjects: 0
Study 12899366 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-Duchenne smiling (high-level)
Number of subjects: 0
Study 12899366 — intervention group
Group type: COMPARATOR
Intervention: Control (no specific smile)
Number of subjects: 0
Study 12899366 — intervention group
Group type: EXPERIMENTAL
Intervention: Lips pressing
Number of subjects: 0
Study 10335040 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuropeptide Y levels in patients with variant angina before, during, and after hyperventilation test
Number of subjects: 38
Study 10335040 — intervention group
Group type: EXPERIMENTAL
Intervention: Thromboxane B2 levels in patients with variant angina during hyperventilation test
Number of subjects: 38
Study 10335040 — intervention group
Group type: COMPARATOR
Intervention: Neuropeptide Y levels in patients with chronic stable angina pectoris
Number of subjects: 38
Study 10335040 — intervention group
Group type: COMPARATOR
Intervention: Thromboxane B2 levels in patients with chronic stable angina pectoris
Number of subjects: 38
Study 10335040 — intervention group
Group type: COMPARATOR
Intervention: Neuropeptide Y levels in healthy controls
Number of subjects: 38
Study 10335040 — intervention group
Group type: COMPARATOR
Intervention: Thromboxane B2 levels in healthy controls
Number of subjects: 38
Study 8602379 — intervention group
Group type: EXPERIMENTAL
Intervention: clarithromycin 250 mg
Number of subjects: 40
Study 8602379 — intervention group
Group type: COMPARATOR
Intervention: doxycycline 100 mg twice/day for 7 days
Number of subjects: 40
Study 2813982 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambroxol 75 mg once a day after breakfast for 30 days
Number of subjects: 20
Study 2813982 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 1069366 — intervention group
Group type: EXPERIMENTAL
Intervention: i.v. pulse doses of 13‐nle‐m (0.05, 0.1, 0.2, and 0.4 mug/kg)
Number of subjects: 19
Study 1069366 — intervention group
Group type: COMPARATOR
Intervention: i.v. bolus injections of 0.6 mug/kg pentagastrin
Number of subjects: 19
Study 1069366 — intervention group
Group type: EXPERIMENTAL
Intervention: i.v. infusions of 13‐nle‐m (0.1, 0.2, and 0.4 mug/kg‐h)
Number of subjects: 19
Study 1069366 — intervention group
Group type: COMPARATOR
Intervention: i.v. pulse dose of 0.1 mug/kg 13‐nle‐m with concomitant atropine
Number of subjects: 19
Study 11450926 — intervention group
Group type: EXPERIMENTAL
Intervention: Outreach visit
Number of subjects: 38
Study 11450926 — intervention group
Group type: COMPARATOR
Intervention: Offer of an outreach visit
Number of subjects: 38
Study 11450926 — intervention group
Group type: COMPARATOR
Intervention: Acceptance of a visit
Number of subjects: 38
Study 11450926 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronidazole use
Number of subjects: 38
Study 30500351 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal tDCS
Number of subjects: 0
Study 30500351 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 0
Study 29493409 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief Cognitive-Behavioral Therapy (CBT)
Number of subjects: 176
Study 29493409 — intervention group
Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 176
Study 26611499 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored education
Number of subjects: 201
Study 26611499 — intervention group
Group type: EXPERIMENTAL
Intervention: Untailored education
Number of subjects: 201
Study 26611499 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 201
Study 24709026 — intervention group
Group type: EXPERIMENTAL
Intervention: New Nordic Diet (NND) school meals
Number of subjects: 834
Study 24709026 — intervention group
Group type: COMPARATOR
Intervention: Control (usual packed lunches)
Number of subjects: 834
Study 22460459 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin 2x5 mg daily
Number of subjects: 42
Study 22460459 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study 20131565 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast Cancer Recovery Program (exercise and relaxation program)
Number of subjects: 32
Study 20131565 — intervention group
Group type: COMPARATOR
Intervention: Health professionals' recommendations (control)
Number of subjects: 32
Study 17601560 — intervention group
Group type: EXPERIMENTAL
Intervention: Morning dosing of sustained-release morphine sulfate
Number of subjects: 45
Study 17601560 — intervention group
Group type: COMPARATOR
Intervention: Evening dosing of sustained-release morphine sulfate
Number of subjects: 45
Study 17601560 — intervention group
Group type: EXPERIMENTAL
Intervention: Both morning and evening dosing
Number of subjects: 45
Study 15754238 — intervention group
Group type: EXPERIMENTAL
Intervention: Graf's ligamentoplasty
Number of subjects: 52
Study 15754238 — intervention group
Group type: COMPARATOR
Intervention: Dorsoventral fusion
Number of subjects: 52
Study 11890840 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin users
Number of subjects: 1037
Study 11890840 — intervention group
Group type: COMPARATOR
Intervention: Higher LDL cholesterol levels
Number of subjects: 1037
Study 11890840 — intervention group
Group type: COMPARATOR
Intervention: Reduction in LDL cholesterol levels
Number of subjects: 1037
Study 11890840 — intervention group
Group type: COMPARATOR
Intervention: Higher total and LDL cholesterol levels
Number of subjects: 1037
Study 11890840 — intervention group
Group type: COMPARATOR
Intervention: High-density lipoprotein cholesterol and triglyceride levels
Number of subjects: 1037
Study 9521487 — intervention group
Group type: EXPERIMENTAL
Intervention: L-arginine (30 g or 6 g, intravenous infusion for 30 min)
Number of subjects: 20
Study 9521487 — intervention group
Group type: EXPERIMENTAL
Intervention: L-arginine (10 microM-2.5 mM, in vitro preincubation)
Number of subjects: 20
Study 9521487 — intervention group
Group type: EXPERIMENTAL
Intervention: L-arginine infusion
Number of subjects: 20
Study 7543691 — intervention group
Group type: EXPERIMENTAL
Intervention: Human albumin (6 g per liter of extracted liquid)
Number of subjects: 16
Study 7543691 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextran 70 (6 g per liter of extracted liquid)
Number of subjects: 16
Study 2650701 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraarticular bupivacaine (Marcaine)
Number of subjects: 79
Study 2650701 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 79
Study 1071676 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 10
Study 1071676 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 10
Study 30923816 — intervention group
Group type: EXPERIMENTAL
Intervention: Glecaprevir/Pibrentasvir (G/P) treatment for 8-16 weeks
Number of subjects: 2369
Study 30923816 — intervention group
Group type: EXPERIMENTAL
Intervention: Glecaprevir/Pibrentasvir (G/P) treatment
Number of subjects: 2369
Study 30325178 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegvisomant (PEGV), average daily dose increased from 12.8 mg (year 1) to 18.9 mg (year 10)
Number of subjects: 2090
Study 30325178 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegvisomant (PEGV)
Number of subjects: 2090
Study 26797837 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant radiochemotherapy (50 Grays over six weeks and four cycles of mFOLFOX6 chemotherapy)
Number of subjects: 70
Study 26797837 — intervention group
Group type: COMPARATOR
Intervention: Surgery alone (control group)
Number of subjects: 70
Study 23650880 — intervention group
Group type: EXPERIMENTAL
Intervention: Small gauze dressings (n=19)
Number of subjects: 41
Study 23650880 — intervention group
Group type: COMPARATOR
Intervention: Large gauze dressings (n=22)
Number of subjects: 41
Study 22203835 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fructose diet (150g per day)
Number of subjects: 20
Study 22203835 — intervention group
Group type: EXPERIMENTAL
Intervention: High-glucose diet (150g per day)
Number of subjects: 20
Study 22203835 — intervention group
Group type: COMPARATOR
Intervention: Balanced weight-maintaining diet
Number of subjects: 20
Study 19417620 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrocardiograms in patients over 50 years of age
Number of subjects: 1149
Study 19417620 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrocardiograms in patients with risk factors (age > 65, history of heart failure, high cholesterol, angina, myocardial infarction, severe valvular disease)
Number of subjects: 1149
Study 19417620 — intervention group
Group type: COMPARATOR
Intervention: Electrocardiograms in patients without risk factors
Number of subjects: 1149
Study 19417620 — intervention group
Group type: EXPERIMENTAL
Intervention: Model sensitivity
Number of subjects: 1149
Study 19417620 — intervention group
Group type: EXPERIMENTAL
Intervention: Age greater than 65 years
Number of subjects: 1149
Study 17126918 — intervention group
Group type: EXPERIMENTAL
Intervention: Ribosomal immunotherapy (one tablet a day, 8 days a month for 3 months)
Number of subjects: 160
Study 17126918 — intervention group
Group type: COMPARATOR
Intervention: Placebo (same dosage for the same period)
Number of subjects: 160
Study 15962569 — intervention group
Group type: EXPERIMENTAL
Intervention: Eruption times of permanent teeth in females
Number of subjects: 1396
Study 15962569 — intervention group
Group type: EXPERIMENTAL
Intervention: Eruption times of permanent teeth in males
Number of subjects: 1396
Study 15962569 — intervention group
Group type: EXPERIMENTAL
Intervention: Eruption sequence of teeth
Number of subjects: 1396
Study 15962569 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of tooth eruption in both jaws
Number of subjects: 1396
Study 15962569 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall findings
Number of subjects: 1396
Study 11313088 — intervention group
Group type: COMPARATOR
Intervention: Antidepressants (pharmacotherapy)
Number of subjects: 167
Study 11313088 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined therapy (antidepressants + 16 sessions of Short Psychodynamic Supportive Psychotherapy)
Number of subjects: 167
Study 9138281 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 mg, 100 mg or 300 mg lamivudine daily for 6 months
Number of subjects: 13
Study 8184968 — intervention group
Group type: EXPERIMENTAL
Intervention: ANP (2.0 pmol.kg‐1.min‐1 for 5 h) + BNP (2.0 pmol.kg‐1.min‐1 for 2 h)
Number of subjects: 8
Study 8184968 — intervention group
Group type: EXPERIMENTAL
Intervention: ANP + BNP
Number of subjects: 8
Study 2908102 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabergoline 0.3 mg
Number of subjects: 8
Study 2908102 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabergoline 0.6 mg
Number of subjects: 8
Study 2908102 — intervention group
Group type: COMPARATOR
Intervention: Bromocriptine 2.5 mg (Control)
Number of subjects: 8
Study 2908102 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabergoline 0.3-0.6 mg (repeated administration)
Number of subjects: 8
Study 2908102 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabergoline 0.6 mg (increased dose)
Number of subjects: 8
Study 2908102 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabergoline (any dose)
Number of subjects: 8
Study 29210921 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotics administration during late pregnancy and first 6 months of life
Number of subjects: 1223
Study 29210921 — intervention group
Group type: COMPARATOR
Intervention: Placebo administration during late pregnancy and first 6 months of life
Number of subjects: 1223
Study 28175315 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxifloxacin (400 mg) co-administered with rifampicin, isoniazid, and pyrazinamide
Number of subjects: 58
Study 28175315 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxifloxacin (400 mg) co-administered with rifampicin, isoniazid, and pyrazinamide in HIV co-infected patients on efavirenz-based ART
Number of subjects: 58
Study 28175315 — intervention group
Group type: COMPARATOR
Intervention: Moxifloxacin alone (single dose) after TB treatment completion
Number of subjects: 58
Study 23840308 — intervention group
Group type: EXPERIMENTAL
Intervention: Geriatric liaison intervention
Number of subjects: 260
Study 23840308 — intervention group
Group type: COMPARATOR
Intervention: Standard care (usual care)
Number of subjects: 260
Study 21824325 — intervention group
Group type: EXPERIMENTAL
Intervention: Nevirapine treatment
Number of subjects: 72
Study 18238788 — intervention group
Group type: EXPERIMENTAL
Intervention: Abatacept
Number of subjects: 0
Study 18238788 — intervention group
Group type: COMPARATOR
Intervention: Control treatments
Number of subjects: 0
Study 18238788 — intervention group
Group type: EXPERIMENTAL
Intervention: RAPID3
Number of subjects: 0
Study 18238788 — intervention group
Group type: EXPERIMENTAL
Intervention: DAS28
Number of subjects: 0
Study 18238788 — intervention group
Group type: EXPERIMENTAL
Intervention: Other RAPID-based indices
Number of subjects: 0
Study 16783767 — intervention group
Group type: EXPERIMENTAL
Intervention: Geriatric Depression Scale‐15 (GDS‐15) Farsi version
Number of subjects: 204
Study 16783767 — intervention group
Group type: EXPERIMENTAL
Intervention: Geriatric Depression Scale‐15 (GDS‐15)
Number of subjects: 204
Study 16783767 — intervention group
Group type: EXPERIMENTAL
Intervention: Geriatric Depression Scale‐11 (GDS‐11)
Number of subjects: 204
Study 12966542 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccine therapy (n = 13)
Number of subjects: 19
Study 12966542 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control, n = 6)
Number of subjects: 19
Study 11194427 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate 30% maternal dietary energy restriction
Number of subjects: 0
Study 11194427 — intervention group
Group type: COMPARATOR
Intervention: Control group with similar dietary intake (6,845 kJ)
Number of subjects: 0
Study 9426796 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral group program plus nicotine gum
Number of subjects: 0
Study 9426796 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral group program plus appetite suppressant gum
Number of subjects: 0
Study 9426796 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral group program plus placebo chewing gum
Number of subjects: 0
Study 8218760 — intervention group
Group type: EXPERIMENTAL
Intervention: TJ-43 (2.5 g three times daily)
Number of subjects: 42
Study 8218760 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study 3622555 — intervention group
Group type: EXPERIMENTAL
Intervention: F(ab')2
Number of subjects: 14
Study 3622555 — intervention group
Group type: COMPARATOR
Intervention: MAB
Number of subjects: 14
Study 28406066 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemedicine consultation
Number of subjects: 282
Study 28406066 — intervention group
Group type: COMPARATOR
Intervention: Usual consultation
Number of subjects: 282
Study 26516124 — intervention group
Group type: EXPERIMENTAL
Intervention: DSEK
Number of subjects: 26
Study 26516124 — intervention group
Group type: COMPARATOR
Intervention: nDSEK
Number of subjects: 26
Study 25129395 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluralaner (25-56 mg/kg; Bravecto™)
Number of subjects: 224
Study 25129395 — intervention group
Group type: COMPARATOR
Intervention: Spinosad (30-60 mg/kg; Comfortis®) with amitraz collar (9%; Preventic®)
Number of subjects: 224
Study 22944002 — intervention group
Group type: EXPERIMENTAL
Intervention: l‐dopa 'on'/DBS 'on'
Number of subjects: 0
Study 22944002 — intervention group
Group type: EXPERIMENTAL
Intervention: l‐dopa 'on'/DBS 'off'
Number of subjects: 0
Study 22944002 — intervention group
Group type: EXPERIMENTAL
Intervention: l‐dopa 'off'/DBS 'on'
Number of subjects: 0
Study 22944002 — intervention group
Group type: EXPERIMENTAL
Intervention: l‐dopa 'off'/DBS 'off'
Number of subjects: 0